ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaBusiness Wire • 09/16/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the FirmBusiness Wire • 09/14/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the FirmBusiness Wire • 09/14/22
ADC Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare ConferenceBusiness Wire • 09/06/22
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible NotesBusiness Wire • 08/15/22
ADC Therapeutics SA (ADCT) CEO Ameet Mallik on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdatesBusiness Wire • 08/09/22
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022Business Wire • 08/02/22
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid TumorsBusiness Wire • 07/27/22
ADC Therapeutics SA (ADCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/26/22
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell LymphomaBusiness Wire • 07/20/22
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical TrialBusiness Wire • 07/11/22
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International TerritoriesBusiness Wire • 07/08/22
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer AgentsBusiness Wire • 06/29/22
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved MedicationsBenzinga • 06/13/22
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin LymphomaBusiness Wire • 06/10/22
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid CongressBusiness Wire • 05/12/22
ADC Therapeutics SA (ADCT) CEO Ameet Mallik on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/22
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdatesBusiness Wire • 05/09/22